Roche Pharma reviews the HTA Core Model® from a pharmaceutical perspective

In a report published in December 2014, Roche Pharma reviews the usefulness of the EUnetHTA Core model® for Roche’s internal HTA assembling, storing and sharing purposes. In a report published in December 2014, Roche Pharma reviews the usefulness of the EUnetHTA Core model® for Roche’s internal HTA assembling, storing and sharing purposes. The report focuses […]

WP7 SG2 Position paper on how to decide on the appropriate study design for AEG available

WP7 Subgroup 2 is pleased to announce the publication of the Position paper on how to decide on the appropriate study design for primary research arising from HTA reports. This document is one of two WP7 SG2 methodological documents aiming to help HTA authors/systematic reviewers in defining their recommendations for Additional Evidence Generation (AEG). This […]

WP7 SG2 Position paper on how to best formulate research recommendations for AEG

This document is one of two WP7 SG2 methodological documents aiming to help HTA authors/systematic reviewers in defining their recommendations for Additional Evidence Generation (AEG). It is focusing on providing a structured approach for the identification of research gaps and improving the presentation of research recommendations arising from HTA reports. Both uncertainties related to the […]

WP7-SG3 “Therapeutic medical devices” guideline

This guideline on “Therapeutic medical devices”, with answered comments from the SAG / Public consultation, is the last guideline of WP7 Subgroup 3 in JA2. Comments_answers_GL_Ther_medical_devices Therapeutic medical devices_Guideline_Final Nov 2015

WP7 SG2 Core protocol Pilot for AEG available

WP7 Subgroup 2 is pleased to announce the publication of its final deliverable – the Core protocol Pilot for Additional Evidence Generation (AEG). This pilot consists of two parts: – Defining core elements of a study protocol for AEG and developing the template of a Core protocol for AEG (section 1) – Testing the developed […]

WP5 Strand A – Procedure Manual V 4

This document describes processes planned for conducting pilot rapid assessments for pharmaceuticals. Since the Procedure Manual is a living document, further changes can be expected due to experiences gathered throughout JA2. 2012123627 – Procedure_manual_REA pilots_WP5_Strand A

Training course for all EUnetHTA Stakeholders, Apr. 23rd, 2015

Presentations from the 3rd face to face training course for EUnetHTA Stakeholders organised by JA2WP2; April 23rd, Brussels. Brief introduction to EUnetHTA and its Tools, Marianne Klemp, NOKC The HTA Core Model® A brief introduction, Anna Nachtnebel, LBI-HTA How to use HTA for decision-making based on HTA Core Information, Anna Nachtnebel, LBI-HTA, Simone Warren, ZIN […]

The 5th pilot rapid assessment of WP5 JA2 Strand B on “Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation” is now available.

The purpose of the assessment is to address the research question whether the use of the technologies in question is more effective and/or safer than their comparators, which were chosen based on CE mark indications, recommendations in clinical guidelines for the treatment of MR and EUnetHTA guidelines. Final version of the assessment was published in […]